Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
    (Date:7/2/2015)... , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen Microsoft ... help it move to Office 365.      ... provides small to medium-sized companies in the bio-tech sector ... aspects of the purchasing cycle to help them obtain ...
    (Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
    (Date:7/1/2015)... -- Isagenix International, a leading global health and wellness ... and three Bronze Stevie® Awards at the 2015 Annual ... this month.The American Business Awards ... the U.S. "Winning is a tremendous ... cultivating talent, creating a unified team, and crafting the ...
    Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
    ... A company whose fuel technology was developed at the ... of Wisconsin-Madison has been acquired by Xethanol Corp. ... Inc. (XTI), was a wholly owned subsidiary of ... Fla. , ,Xethanol Corp. is a biotechnology-driven ethanol production ...
    ... - A Harvard research team announced on Sunday ... skin cells, a finding that could affect some of ... research avenues. But a University of Wisconsin-Madison professor cautions ... article published on the Web site of the research ...
    ... -- Wisconsin has made significant progress in improving business ... to relieve investment restrictions if the state is to ... heard on Tuesday. , ,"Today it is easier to ... to invest in emerging, growth Wisconsin companies," said Terry ...
    Cached Biology Technology:Harvard advance improves stem cell research; not a medical revolution 2Regulations still stymie business investment in high-growth companies 2Regulations still stymie business investment in high-growth companies 3Regulations still stymie business investment in high-growth companies 4
    (Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
    (Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
    (Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
    Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
    ... and Saint Petersburg, Russia An international team of ... University of California, San Diego, have developed a new ... faster and more accurately. The new algorithm, called SPAdes, ... submitted to standard cloning techniqueswhat researchers refer to as ...
    ... America,s leading avian experts will gather in Vancouver next week ... bird biology and conservation. It,s the first time the ... the conference comes in the wake of sweeping reports indicating ... "We can manage habitat for Purple Martins breeding on ...
    ... 2012The Journal of the Pediatric Infectious Diseases Society ... most rigorous evaluation to date of the impact on ... hospital using a prospective-audit-with-feedback antibiotic stewardship program (ASP). ... children,s hospitals of the Child Health Corporation of America. ...
    Cached Biology News:US-Russian collaboration develops new method for sequencing dark matter of life from a single cell 2US-Russian collaboration develops new method for sequencing dark matter of life from a single cell 3Major migration of bird experts flock to Vancouver 2Major migration of bird experts flock to Vancouver 3First antibiotic stewardship probed in the Journal of the Pediatric Infectious Diseases Society 2
    ... Savant SpeedVac™ Concentrators set the standard for sample ... SpeedVac with large chamber uses a combination of ... samples in a single run. , SC210A comes ... for long lasting chemical compatibility ...
    ... (for aqueous, other low volatility and noxious ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
    ... Standard Bio for vacuum concentrator/centrifugal evaporator ... biology and biochemistry for rapid and safe ... can be expanded with pumps, different of ... rotors (eliminating sample loss by transfer), ensuring ...
    ... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
    Biology Products: